R

R&G PharmaStudies Co Ltd
SZSE:301333

Watchlist Manager
R&G PharmaStudies Co Ltd
SZSE:301333
Watchlist
Price: 60.15 CNY 3.89% Market Closed
Market Cap: 5.8B CNY
Have any thoughts about
R&G PharmaStudies Co Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

34.3
Current
24.8
Median
23.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
34.3
=
Enterprise Value
4.1B CNY
/
EBIT
119m CNY
All Countries
Close

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
18.2
2-Years Forward
EV/EBIT
15.5
3-Years Forward
EV/EBIT
N/A

See Also

Discover More